Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis (Q38092009)

From Wikidata

Jump to navigation Jump to search

scientific article published on April 2013

Language	Label	Description	Also known as
English	Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis	scientific article published on April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Katherine J. Aitchison

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Ian Chi Kei Wong

6

object named as

Ian C K Wong

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Noor B Almandil

object named as

Noor B Almandil

1

0 references

Macey L. Murray

object named as

Macey L Murray

3

0 references

author name string

Ying Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Frank M C Besag

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Pediatric Drugs

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

139-150

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Treatment with atypical antipsychotics: new indications and new populations

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A review of the effect of atypical antipsychotics on weight

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Increased prescribing trends of paediatric psychotropic medications

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Trends in psychotropic medication costs for children and adolescents, 1997-2000.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

The pharmacology and toxicology of atypical antipsychotic agents

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

The metabolic effects of antipsychotic medications

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Childhood obesity: public-health crisis, common sense cure

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Predictability of childhood adiposity and insulin for developing insulin resistance syndrome (syndrome X) in young adulthood: the Bogalusa Heart Study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Childhood adversities associated with risk for eating disorders or weight problems during adolescence or early adulthood

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Review on the current use of antipsychotic drugs in children and adolescents.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Age onset subtypes of obsessive compulsive disorder: differences in clinical response to treatment with clomipramine.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A placebo-controlled trial of risperidone in Tourette syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A double-blind pilot study of risperidone in the treatment of conduct disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone in children with autism and serious behavioral problems

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone in children with autism: randomized, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Olanzapine in the treatment of post-traumatic stress disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

A 1-year open-label trial of olanzapine in school-age children with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Olanzapine induces remarkable weight gain in adolescent patients

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Change in sexual dysfunction with aripiprazole: a switching or add-on study

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

Principles of and Procedures for Systematic Reviews

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0016-6

21 January 2018

The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of atypical antipsychotics in pediatric bipolar disorder.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parental neglect during childhood and increased risk of obesity in young adulthood

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel antipsychotic medications in the treatment of children and adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aripiprazole versus other atypical antipsychotics for schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and tolerability of quetiapine versus divalproex for the treatment of impulsivity and reactive aggression in adolescents with co-occurring bipolar disorder and disruptive behavior disorder(s)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolactin levels during long-term risperidone treatment in children and adolescents

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine versus placebo in the treatment of borderline personality disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/23519708

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40272-013-0016-6

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38092009&oldid=2201259420"